Johns Hopkins University
- NIH Protein Capture Reagents Program
- East Baltimore Startup Among Companies Showcased at White House Demo Day
- Science and Technology Park at Johns Hopkins
NYU Langone Medical Center
- Baseline Antibody Profiles Predict Toxicity in Melanoma Patients Treated with Immune Checkpoint Inhibitors
- Arrayjet is the Global Supplier of the World’s Largest Full-Length, Functional Human Protein Microarray
- CDI Laboratories: The Largest Human Proteome Array (HuProt)
Cambridge Protein Arrays
CDI Laboratories, Inc. HuProt™ protein microarray provided important data on a recent high impact paper comparing the immune profiles of MIS-C, healthy children and individuals with COVID-19 (as published in CELL).
AUG 20, 2020 – CDI Labs Launches its SARS-CoV-2 (COVID19) service platform
CDI Laboratories, Inc. announced the addition of its SARS-CoV-2 (COVID19) assay platform. The assays use CDI’s VirScan service which can detect antibodies to 1345 individual viral strains representing species from 76 viral genera. This is coupled with CDI’s 2 in 1 SARS-CoV-2 antigen microarray which contains overlapping SARS-CoV-2 peptides as well as full-length proteins.
Edinburgh’s Arrayjet has signed a seven-figure deal with CDI Laboratories to further the US firm’s research and development programme. The contract is said to be worth in the region of $1 million (£797,000) and is the second installation of Arrayjet equipment at CDI.
CDI Laboratories, Inc. Antygen Division announced the addition of two powerful new assays to its biomarker discovery platform. HuScan and VirScan are the first commercial use of PhIP-seq technology developed in the laboratories of Steve Elledge & Ben Larman. HuScan detects antibodies against the entire human proteome via long peptides on the surface of bacteriophages, antibody pulldown and sequencing readouts. VirScan detects antibodies against the proteomes of every viral strain known to infect humans in the same manner. These portfolio additions further strengthen CDI as a global leader in patient-derived antibody biomarker discovery.
Recent findings by Gowen et al. “Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors” (J Transl Med  16:82) demonstrate that HuProt™ protein microarrays can be used to discover novel immuno-oncology biomarkers for predicting patient toxicity to anti-CTLA-4 and anti-PD1. According to CDI scientists –these results might extend to predicting treatment outcomes for other I-O therapies, targeted therapies, and traditional cancer treatments.
CDI Laboratories, Inc. has announced that ~2,000 new recombinant proteins have been added to HuProt™ – its human proteome microarray. This addition now means that CDI’s HuProt v4.0 array “v4.0 now contains over 21,000 human proteins and protein isoforms, including >81% of canonically expressed proteins as defined by the Human Protein Atlas.” CDI’s HuProt™ array is available as a stand-alone product or as part of CDI’s services platform. The addition of this additional content further strengthens CDI’s position as a global leader in microarray production, content and application development.
A newly published article in Nature Methods describes CDI Laboratories’ participation in the NIH Protein Capture Reagents Program (PCRP). CDI’s patented method of antibody development (FastMAb®) features the use of CDI’s HuProt™ microarray (containing 81% of the human proteome) to ensure that the antibodies produced are truly mono-specific.
Newly published research in the Journal of Molecular and Cellular Proteomics* describes a collection of autoantibody biomarkers for early detection of lung cancer. The biomarkers were discovered using the HuProt™ human proteome microarray (CDI Laboratories), the largest collection of full-length human proteins in the world.
CDI Laboratories, Inc. has announced that over 1,000 new recombinant proteins will be added to HuProt™ – its human proteome microarray. With 81% of the human proteome available in a powerful and economical analytical platform*, the Company greatly strengthens its position as a global leader in microarray production, content and application development.
CDI Laboratories (CDI) has granted exclusive worldwide distribution rights of its collection of over 2500 transcription factor monospecific monoclonal antibodies to NeoBiotechnologies. The antibodies were developed through CDI’s participation in the NIH Protein Capture Reagents Program. The antibodies have been certified monospecific using the CDI HuProt™ microarray which contains 75% of the human proteome. The agreement also includes future antibodies against critical cancer diagnostic markers developed by CDI (using its Fast-MAb® monoclonal antibody development technology) and specificity validation on the HuProt microarray. NeoBiotechnologies will be evaluating all antibodies for use in immunohistochemistry (IHC) and will distribute through NeoBiotechnologies extensive worldwide channels.